Enanta Pharma (ENTA) Misses Q4 EPS by 2c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.27), $0.02 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $20.32 million versus the consensus estimate of $22.87 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance